SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Novacare (NOV) breaking out... -- Ignore unavailable to you. Want to Upgrade?


To: Sigmund who wrote (291)6/19/1998 1:41:00 PM
From: Todd D. Wiener  Read Replies (2) | Respond to of 420
 
BA Rob Stephens today issued an update on NOV.

Here's the upshot:

BUY
$0.22 for Q4.
Expects no effect on NOV from Salary Equivalency and Prospective Payment issues with Medicare.
Vencor's problems are company-specific. NOV's management has planned for years, and the restructuring charge creates adequate reserves, insuring maximum profits under the PPS.
Contrary to some rumor, NOV is not for sale.
BARS is confident that NOV will meet their estimates into the foreseeable future.

Sounds right to me.

Todd